ES2093078T3 - Compuesto farmaceuticamente activo sobre el snc. - Google Patents

Compuesto farmaceuticamente activo sobre el snc.

Info

Publication number
ES2093078T3
ES2093078T3 ES91304935T ES91304935T ES2093078T3 ES 2093078 T3 ES2093078 T3 ES 2093078T3 ES 91304935 T ES91304935 T ES 91304935T ES 91304935 T ES91304935 T ES 91304935T ES 2093078 T3 ES2093078 T3 ES 2093078T3
Authority
ES
Spain
Prior art keywords
elevated
hydrogen
halo
cns
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304935T
Other languages
English (en)
Spanish (es)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2093078T3 publication Critical patent/ES2093078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES91304935T 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc. Expired - Lifetime ES2093078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
ES2093078T3 true ES2093078T3 (es) 1996-12-16

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304935T Expired - Lifetime ES2093078T3 (es) 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc.

Country Status (25)

Country Link
EP (2) EP0679645A1 (enExample)
JP (1) JPH06340634A (enExample)
KR (1) KR920000733A (enExample)
AT (1) ATE141263T1 (enExample)
AU (2) AU652753B2 (enExample)
CA (1) CA2043640A1 (enExample)
CZ (1) CZ281070B6 (enExample)
DE (1) DE69121317T2 (enExample)
DK (1) DK0459819T3 (enExample)
ES (1) ES2093078T3 (enExample)
FI (1) FI912623A7 (enExample)
GB (1) GB9012316D0 (enExample)
GR (1) GR3021237T3 (enExample)
HU (2) HUT58707A (enExample)
IE (1) IE911861A1 (enExample)
IL (2) IL113599A (enExample)
MY (2) MY109958A (enExample)
NO (1) NO180375C (enExample)
NZ (3) NZ238360A (enExample)
PL (2) PL170373B1 (enExample)
PT (1) PT97827B (enExample)
RU (1) RU2091374C1 (enExample)
SK (1) SK278444B6 (enExample)
TW (1) TW224460B (enExample)
ZA (1) ZA914165B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
CH685978A5 (fr) * 1991-01-30 1995-11-30 Wellcome Found Comprimes dispersables dans l'eau.
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
MY123528A (en) 1999-09-16 2006-05-31 Mitsubihsi Tanabe Pharma Corp Aromatic nitrogen-containing 6-membered cyclic compounds.
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
PL372390A1 (en) * 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP1902028A2 (en) 2005-07-04 2008-03-26 Novo Nordisk A/S Histamine h3 receptor antagonists
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
ATE538116T1 (de) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
RU2769132C2 (ru) 2017-01-10 2022-03-28 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (enExample) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
NO180375C (no) 1997-04-09
PT97827B (pt) 1998-10-30
FI912623A0 (fi) 1991-05-31
HUT58707A (en) 1992-03-30
MY109958A (en) 1997-10-31
NZ248501A (en) 1997-03-24
IL113599A0 (en) 1995-08-31
DE69121317D1 (de) 1996-09-19
NO912100D0 (no) 1991-05-31
EP0459819B1 (en) 1996-08-14
HU211649A9 (en) 1995-12-28
PL170373B1 (pl) 1996-12-31
IE911861A1 (en) 1991-12-04
EP0679645A1 (en) 1995-11-02
PL166656B1 (pl) 1995-06-30
CZ281070B6 (cs) 1996-06-12
AU7809791A (en) 1991-12-05
JPH06340634A (ja) 1994-12-13
ZA914165B (en) 1993-03-01
KR920000733A (ko) 1992-01-29
SK278444B6 (en) 1997-05-07
ATE141263T1 (de) 1996-08-15
CS164391A3 (en) 1992-02-19
EP0459819A3 (en) 1992-03-11
RU2091374C1 (ru) 1997-09-27
AU680252B2 (en) 1997-07-24
HU911826D0 (en) 1991-12-30
IL98330A0 (en) 1992-06-21
NZ272001A (en) 1997-03-24
CA2043640A1 (en) 1991-12-02
AU6745594A (en) 1994-09-15
AU652753B2 (en) 1994-09-08
DE69121317T2 (de) 1997-01-02
NZ238360A (en) 1997-03-24
EP0459819A2 (en) 1991-12-04
DK0459819T3 (da) 1996-09-02
MY136248A (en) 2008-08-29
NO912100L (no) 1991-12-02
PT97827A (pt) 1992-03-31
TW224460B (enExample) 1994-06-01
IL113599A (en) 1997-09-30
NO180375B (no) 1996-12-30
GR3021237T3 (en) 1997-01-31
GB9012316D0 (en) 1990-07-18
FI912623A7 (fi) 1991-12-02
IL98330A (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ES2093078T3 (es) Compuesto farmaceuticamente activo sobre el snc.
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
ES2040234T3 (es) Derivados del tetrahidronaftaleno y medicamentos que los contienen.
NO305478B1 (no) Hydroksyetylaminosulfonamider som retrovirale proteasehemmere
ES2075121T3 (es) Nuevos compuestos triciclicos.
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
ES2121896T3 (es) Derivados de acido hidroxamico como inhibidores de colagenasa.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2118710T3 (es) Nuevos inhibidores de peptidasa.
AR240932A2 (es) "composicion para la proteccion de las plantas de cultivo conttra las acciones nocivas de productos quimicos agresivos, compuestos para uso exclusivo en dicha composicion y un procedimiento para preparar dichos compuestos"
SV1994000028A (es) Nuevas sulfonilamino pirimidinas, ref. 10916 sv.
MX9300735A (es) Derivados de bencimidazolilo, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2105783T3 (es) Inhibidores de metaloproteasas matriciales.
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
ES2067874T3 (es) Derivados de acetamida.
ES2067822T3 (es) Inhibidores de la fosfolipasa a2 isoprenoide y preparaciones que los contienen.
ES2077399T3 (es) Derivados de poli-4-aminopirrol-2-carboxiamida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
ES8705453A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
ES2100396T3 (es) Derivados de 17-(3-furil)- y 17-(4-piridazinil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que los contienen.
ES2176237T3 (es) Derivados de taxano c2 y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 459819

Country of ref document: ES